Saturday, May 14

Program Schedule

MEETING WORKSHOP: NK Cells in the Clinic

Separate Registration Required 

7:00 am – 6:00 pm: Registration Open                                                       
Conference Foyer

8:30 am - 10:00 am: NK Cells in the Clinic Workshop I                            
Estero Ballroom

Todd Fehniger, Washington University School of Medicine
Dean Lee, Nationwide Children's Hospital

8:30 am – 8:50 am          
Jeff Miller, University of Minnesota

8:50 am – 9:10 am         
Katy Rezvani, University of Texas

9:10 am – 9:30 am         
Evelyn Ullrich, Goethe University Frankfurt

9:30 am – 9:40 am         
1  CD16ahigh NK cell infiltration predicts improved survival in high grade ovarian cancer and demonstrates prognostically beneficial spatial relationships with T cells and macrophages
Sarah Nersesian, Dalhousie University                      

9:40 am – 9:50 am          
2 Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity
Laura Sanz Ortega, Karolinska Institutet    

9:50 am – 10:00 am       
Circulating natural killer cells differentiated ex vivo into tissue-resident cells represent a novel class of cancer immunotherapies
Nina Horowitz, Stanford University                

10:00 am - 10:30 am:  Coffee Break                                                                
Estero Prefunction

10:30 am - 12:00 pm:  NK Cells in the Clinic Workshop II                           
Estero Ballroom

Michael Verneris, University of Colorado

10:30 am – 10:50 am     
Todd Fehniger, Washington University School of Medicine

10:50 am – 11:10 am     
Veronika Bachanova, University of Minnesota

11:10 am – 11:30 am     
Eric Vivier, CIML

11:30 am – 11:40 am     
4 Thymic reprogramming: Acute systemic inflammation changes the cellular output of the thymus towards NK cell production
Peter Tougaard, VIB-UGent           

11:40 am – 11:50 am     
5 A Tri-specific killer engager (TriKE®) targeting prostate-specific membrane antigen (PSMA) enhances NK cell killing of prostate cancer
Gwen Phung, University of Minnesota-Twin Cities

11:50 am – 12:00 pm     
6 A novel memory-like NK cell CAR targeting proximal mesothelin domain shows promising pre-clinical activity in ovarian cancer using cell lines and patient derived organoids
Mubin Tarannum, Dana Farber Cancer Institute

12:00 pm – 12:45 pm:  Roundtable Discussion                                             
Estero Ballroom

Todd Fehniger, Washington University School of Medicine

12:45 pm – 2:00 pm: Lunch                                                                              
Calusa Terrace



4:45 pm - 5:00 pm: Welcome to NK2022                                                  
Estero Ballroom

Megan Cooper, Washington University School of Medicine
Todd Fehniger, Washington University School of Medicine

5:00 pm - 6:00 pm: Keynote: 50 Years of NK Cells                                  
Estero Ballroom

Megan Cooper, Washington University School of Medicine
Todd Fehniger, Washington University School of Medicine

Prof. Angela Santoni is Emeritus of Immunology and Immunopathology at the Sapienza University of Rome and Scientific Director of the Pasteur Institute-Italia. She was Vice President and President of the International Society of Natural Immunity, and President of the Italian Society of Immunology, Clinical Immunology and Allergology, Currently, she is member of the Council of International Union Immunological Societies. Over the years, she has been involved in studying several aspects of NK cell biology, providing relevant contributions on the signaling events leading to NK cell adhesion, migration and effector functions; on the modulation of NK activating stress ligand expression and NK cell recognition; on the role of NK cells in the immunosurveillance against senescent cells; on the role of tumor-microenvironment in the modulation of NK/ILC functions.

Dr. Michael Caligiuri is President of the City of Hope National Medical Center in Los Angeles, California, where he holds the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He is a physician – scientist whose basic and translational work has focused on immunotherapy for both liquid and solid tumors. Dr. Caligiuri is an elected member of the American Society for Clinical Investigation, the American Association of Physicians, and the USA National Academy of Medicine; elected Fellow in the American Association for the Advancement of Science and the American Association for Cancer Research (AACR) Academy. He is past president of the Association for American Cancer Institutes, the Society of Natural Immunity, and the AACR. His laboratory has studied human natural killer (NK) cells for 35 years with over 400 original peer-reviewed publications on NK cells and/or cancer. Over the years, the Caligiuri laboratory has elucidated the sites, stages, cytokines and molecular mechanisms involved in the differentiation of human NK cells from CD34(+) hematopoietic stem cells, and the discovery of IL-15 as the key cytokine for human NK cell development, survival, growth, and activation, and is currently pioneering CAR-engineering of NK cells for cancer immunotherapy. Dr. Caligiuri has designed and conducted clinical studies modulating NK cells for over 1,000 patients with cancer.


6:00 pm - 8:00 pm: Welcome Reception                     
Waterfall Pool Deck and Cypress Courtyard

Last updated: May 2, 2022